186 related articles for article (PubMed ID: 2380132)
1. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
Varthakavi PK; Turakhia DP; Sharma SS; Salgaonkar DS; Nihalani KD; Joshi VR
J Assoc Physicians India; 1990 Feb; 38(2):136-40. PubMed ID: 2380132
[TBL] [Abstract][Full Text] [Related]
2. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
3. Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers.
Koskinen P; Kovanen PT; Tuomilehto J; Manninen V
Arch Intern Med; 1992 Jan; 152(1):90-6. PubMed ID: 1728934
[TBL] [Abstract][Full Text] [Related]
4. [Gemfibrozil in the treatment of lipid metabolism disorders].
Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV
Klin Med (Mosk); 1994; 72(1):37-41. PubMed ID: 8196321
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
Wolf HR
Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
[TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil in dyslipidaemia.
Kundu SC; Roxy S; Batabyal SK
J Assoc Physicians India; 1990 Feb; 38(2):156-9. PubMed ID: 2199426
[TBL] [Abstract][Full Text] [Related]
7. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
[TBL] [Abstract][Full Text] [Related]
8. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
Corominas Vilardell A; de Oya Otero M; Escobar Jiménez F; Anguera Vila A; Ariño Armengol B
An Med Interna; 1993 Nov; 10(11):537-41. PubMed ID: 8117868
[TBL] [Abstract][Full Text] [Related]
9. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
[TBL] [Abstract][Full Text] [Related]
10. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
Sommariva D; Branchi A; Pini C; Scandiani L; Orlandi S; Fasoli A
Int J Clin Pharmacol Res; 1988; 8(5):383-92. PubMed ID: 3068163
[TBL] [Abstract][Full Text] [Related]
11. Management of primary mixed hyperlipidemia with lovastatin.
Vega GL; Grundy SM
Arch Intern Med; 1990 Jun; 150(6):1313-9. PubMed ID: 2353864
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of simvastatin in the treatment of hyperlipidemia].
Lu ZL
Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Aug; 21(4):216-8, 253. PubMed ID: 8194433
[TBL] [Abstract][Full Text] [Related]
13. [Cerivastatin-a new synthetic 3-hydroxy-3-methylglutaryl (HMG) inhibitor: effect of 0,2 mg dose in patients with primary hyperlipidemias].
Solov'eva EIu; Rozhkova TA; Tvorogova MG; Kukharchuk VV
Ter Arkh; 1999; 71(8):30-4. PubMed ID: 10515032
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
McCrindle BW; Ose L; Marais AD
J Pediatr; 2003 Jul; 143(1):74-80. PubMed ID: 12915827
[TBL] [Abstract][Full Text] [Related]
15. [Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias].
Bertolami MC; Martinez TL; Faludi AA; Pinto LE; Melo RS; Bismarck ZF; Batlouni M
Arq Bras Cardiol; 1991 May; 56(5):407-12. PubMed ID: 1823741
[TBL] [Abstract][Full Text] [Related]
16. Gemfibrozil in familial and type V hyperlipidaemias. Report of 3 cases.
Varthakavi P; Turakhia DP; Sharma S; Salgaonkar DS; Nihalani KD; Joshi VR
J Assoc Physicians India; 1990 Nov; 38(11):860-2. PubMed ID: 2079473
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
[TBL] [Abstract][Full Text] [Related]
18. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.
Ayyobi AF; McGladdery SH; McNeely MJ; Austin MA; Motulsky AG; Brunzell JD
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1289-94. PubMed ID: 12750118
[TBL] [Abstract][Full Text] [Related]
19. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus.
Tawata M; Miwa I; Tsuchiya K; Ozawa M; Shindo H; Wakasugi M; Onaya T
Arzneimittelforschung; 1995 Jun; 45(6):704-8. PubMed ID: 7646575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
